

September 19, 2019

To
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Sub: **Outcome of Board Meeting held on September 19, 2019**

Dear Sir/Madam,

In continuation to our letter dated September 13, 2019, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 19th September, 2019, have considered & approved the following.

1. Un-audited consolidated financial results of the company for the quarter ended June 30, 2019.
2. The Board also noted that the Sudan was facing serious political instability for quite some time. Since last 3 quarters, the Company was not able to source any sales from Sudan which is reflecting in June quarter's financial results
3. To grant of additional 51546 options to the employees of the Company under ESOS Scheme.

In this connection please find enclosed the copy of Un-audited Consolidated financial Results of the Company for the quarter ended 30th June, 2019 along with Limited Review Report by the Statutory Auditors of the Company as "Annexure-I".

The meeting commenced at 11:00 A.M. and concluded at 6:00 P.M.

The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully,
For **Kilitch Drugs (India) Limited**


Mukund Mehta
Managing Director
DIN: 00147876



Encl: as above



A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

224, Champaklal Industrial Estate,
Sion-Koliwada Road, Sion (East),
Mumbai - 400 022.
Tel : 2402 4909 / 8739
Fax : 2407 1138
E-mail : amghelaniandco@gmail.com

AJIT M. GHELANI
B.Com (Hons), F.C.A., GRAD. C.W.A.

CHINTAN A. GHELANI
B.Com (Hons), F.C.A., C.S

LIMITED REVIEW REPORT

To,
THE BOARD OF DIRECTORS
KILITCH DRUGS (INDIA) LTD.

**LIMITED REVIEW REPORT OF THE UNAUDITED CONSOLIDATED RESULTS OF
KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 30th JUNE, 2019**

1. We have reviewed the accompanying statement of Consolidated Financial Results for the quarter ended 30th June, 2019 ("the Statement") of **Kilitch Drugs (India) Limited** ("the Holding Company") and its' subsidiaries (the Holding Company and its subsidiaries constitute "the Group") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation"), read with Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(B) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

List of Subsidiaries:

1. Monarchy Healthserve Private Limited
2. Kilitch Estro Biotech PLC – Foreign Subsidiary




A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

5. (a) The accompanying Statement includes interim Financial result/statements and other financial information of one subsidiary which reflects, total revenue of Rs. 1.61 Lakhs and total loss after tax of Rs. 23.52 Lakhs for the quarter ended 30th June, 2019 which have been reviewed by us.

(b) We have relied on the unaudited financial statements of one foreign subsidiary, whose financial statements reflect total revenue & total profit/loss of Rs. Nil for the quarter ended 30th June, 2019, as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of these subsidiaries is solely based on such unaudited financial statements as certified by the management. Our conclusion is not modified in respect of these matters.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the management certified financial statement referred in paragraph 5(b) above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company
Chartered Accountants
Firm Registration No.: 103173W



Chintan A. Ghelani
Partner
Membership No.: 104391



ICAI UDIN : 19104391AAAACL6409

Place : Mumbai
Date : 19th September, 2019

KILITCH DRUGS (INDIA) LIMITED
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2019

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com
CIN:L24239MH1992PLC066718

(Rs. in Lakhs)

Sr. No.	Particulars	CONSOLIDATED			
		Three Months Ended			Year Ended
		30/06/2019	31/03/2019	30/06/2018	31/03/2019
		Unaudited	Audited	Unaudited	Audited
1	Income From Operations				
	Net Sales/Income from Operations	1,043.19	1,932.45	2,808.52	8,248.99
	Other Income	137.79	(62.17)	237.67	400.40
	Total Income from Operations	1,180.98	1,870.28	3,046.19	8,649.39
2	Expenses				
	Cost of Materials Consumed	748.97	928.04	1,767.54	4,834.51
	Variation in inventories of finished goods, work-in-progress and Stock-in-Trade	(105.07)	75.34	(55.31)	(17.70)
	Employee Benefit Expenses	133.44	140.88	138.16	528.37
	Finance Cost	15.10	37.91	-	37.91
	Depreciation and Amortisation Expenses	43.63	55.19	47.19	205.11
	Export Product Registration/Commission	124.88	164.65	64.06	683.93
	Other expenses	214.11	330.47	573.17	1,518.60
	Total Expenses	1,175.06	1,732.48	2,534.81	7,790.73
3	Profit/(Loss) before Exceptional items (1-2)	5.92	137.80	511.38	858.66
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) from ordinary activities before tax (3+4)	5.92	137.80	511.38	858.66
6	Less : Tax Expenses				
	Current Income Tax	4.65	90.47	59.12	424.08
	Deferred Tax	20.62	(2.40)	58.07	51.60
7	Net Profit/(Loss) after tax for the period from continuing operations (5-6)	(19.35)	49.73	394.19	382.98
8	Other Comprehensive Income (after Tax)	(37.21)	61.18	(29.59)	(105.69)
9	Total Comprehensive Income (after taxes) (7+8)	(56.56)	110.91	364.60	277.29
10	Net Profit / (Loss) attributable to				
	a) Owner of the Company	(19.35)	49.73	394.19	382.98
	b) Non Controlling interest	-	-	-	-
11	Other Comprehensive Income attributable to				
	a) Owner of the Company	(37.21)	61.18	(29.59)	(105.69)
	b) Non Controlling interest	-	-	-	-
12	Total Income attributable to				
	a) Owner of the Company	(56.56)	110.91	364.60	277.29
	b) Non Controlling interest	-	-	-	-
13	Paid-Up equity share capital (Face Value Rs. 10 per share)	1,541.75	1,535.52	1,373.18	1,535.52
14	Other Equity	-	-	-	-
15	Earnings per share				10,570.21
	(a) Basic (not annualised)	(0.13)	0.34	2.87	2.61
	(b) Diluted (not annualised)	(0.13)	0.34	2.57	2.61




Notes:

1. The above unaudited results for the quarter ended 30th June, 2019 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 19th September, 2019.
2. The statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The company has issued 62,239 Equity Shares under the ESOP scheme at an exercise price of Rs. 10 per equity share during the quarter ended 30th June, 2019.
4. The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
5. The IND AS 115 Revenue from Contract with customers, mandatory for reporting periods beginning on or after April 1, 2018, replaces the existing revenue recognition requirements. The application of IND AS 115 has not impacted the Group's accounting for recognition of revenue.
6. The figures for the quarter ended 31st March, 2019 are the balancing figures between the audited figures in respect of the full financial year and the year-to-date figures up to the third quarter of the said financial year.
7. The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place: Mumbai
Date: 19th September, 2019



For and on behalf of the Board of Directors


Mukund P. Mehta
Managing Director

